Literature DB >> 24568886

The utility of FDG-PET/CT and other imaging techniques in the evaluation of IgG4-related disease.

Hiroyuki Takahashi1, Hiroyuki Yamashita2, Miyako Morooka3, Kazuo Kubota3, Yuko Takahashi1, Hiroshi Kaneko1, Toshikazu Kano1, Akio Mimori1.   

Abstract

OBJECTIVES: This study aimed to evaluate the utility of imaging techniques, including 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), in immunoglobulin (IgG)4-related disease (IgG4-RD).
METHODS: We reviewed eight IgG4-RD patients who were referred to our hospital between August 2006 and April 2012. All cases underwent FDG-PET/CT and brain magnetic resonance imaging (MRI) and endobronchial ultrasonography (EBUS) were also performed in five cases and one case, respectively.
RESULTS: Although nearly all patients with IgG4-RD in this study were negative for CRP (mean 0.22 mg/dL), various organ involvement sites were detected by FDG-PET/CT. In the active phase in two autoimmune pancreatitis (AIP) cases, FDG-PET/CT showed longitudinal and heterogeneous FDG accumulation in the pancreas with FDG uptake in the hilar or mediastinal lymph nodes. Follow-up FDG-PET/CT after therapy in one case revealed that the abnormal FDG uptake in all affected lesions had completely disappeared. In two cases, brain MRI revealed asymptomatic hypertrophic pachymeningitis. In one case, EBUS imaging of mediastinal lymph node swelling was consistent with tortuous vessels with high Doppler signals and hyperechoic strands between lymph nodes.
CONCLUSIONS: When FDG-PET/CT shows FDG accumulation, characteristic of IgG4-RD in organs, without evidence of an associated inflammatory reaction, a diagnosis of IgG4-RD can be made. Treatment effects can be assessed by the disappearance of FDG uptake. A routine brain MRI is useful for detecting asymptomatic hypertrophic pachymeningitis. EBUS may also be useful for differentiating among the etiologies of lymphadenopathy with characteristic sonographic imaging findings.
Copyright © 2014 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT); Brain magnetic resonance imaging (MRI); Endobronchial ultrasonography (EBUS); Hypertrophic pachymeningitis; Immunoglobulin (IgG)4-related disease (IgG4-RD)

Mesh:

Substances:

Year:  2014        PMID: 24568886     DOI: 10.1016/j.jbspin.2014.01.010

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  13 in total

1.  18F-FDG PET/CT in patients with adult-onset Still's disease.

Authors:  Meng-Jie Dong; Cai-Qin Wang; Kui Zhao; Guo-Lin Wang; Mei-Ling Sun; Zhen-Feng Liu; Liqin Xu
Journal:  Clin Rheumatol       Date:  2015-02-26       Impact factor: 2.980

2.  European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations.

Authors:  J-Matthias Löhr; Ulrich Beuers; Miroslav Vujasinovic; Domenico Alvaro; Jens Brøndum Frøkjær; Frank Buttgereit; Gabriele Capurso; Emma L Culver; Enrique de-Madaria; Emanuel Della-Torre; Sönke Detlefsen; Enrique Dominguez-Muñoz; Piotr Czubkowski; Nils Ewald; Luca Frulloni; Natalya Gubergrits; Deniz Guney Duman; Thilo Hackert; Julio Iglesias-Garcia; Nikolaos Kartalis; Andrea Laghi; Frank Lammert; Fredrik Lindgren; Alexey Okhlobystin; Grzegorz Oracz; Andrea Parniczky; Raffaella Maria Pozzi Mucelli; Vinciane Rebours; Jonas Rosendahl; Nicolas Schleinitz; Alexander Schneider; Eric Fh van Bommel; Caroline Sophie Verbeke; Marie Pierre Vullierme; Heiko Witt
Journal:  United European Gastroenterol J       Date:  2020-06-18       Impact factor: 4.623

3.  Focal autoimmune pancreatitis and chronic sclerosing sialadenitis mimicking pancreatic cancer and neck metastasis.

Authors:  Li Sun; Qiang Zhou; David R Brigstock; Su Yan; Ming Xiu; Rong-Li Piao; Yan-Hang Gao; Run-Ping Gao
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 4.  Autoimmune diseases of the brain, imaging and clinical review.

Authors:  Ghazal Shadmani; Tyrell J Simkins; Reza Assadsangabi; Michelle Apperson; Lotfi Hacein-Bey; Osama Raslan; Vladimir Ivanovic
Journal:  Neuroradiol J       Date:  2021-09-07

Review 5.  Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

Authors:  Hiroyuki Yamashita; Kazuo Kubota; Akio Mimori
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

6.  IgG4-related disease in an adolescent with radiologic-pathologic correlation.

Authors:  Renato Cesar Ferreira da Silva; Scott M Lieberman; Henry T Hoffman; Bruno Policeni; Amani Bashir; Richard J H Smith; T Shawn Sato
Journal:  Radiol Case Rep       Date:  2016-12-07

7.  Characteristics of immunoglobulin G4-related aortitis/periaortitis and periarteritis on fluorodeoxyglucose positron emission tomography/computed tomography co-registered with contrast-enhanced computed tomography.

Authors:  Satoshi Yabusaki; Noriko Oyama-Manabe; Osamu Manabe; Kenji Hirata; Fumi Kato; Noriyuki Miyamoto; Yoshihiro Matsuno; Kohsuke Kudo; Nagara Tamaki; Hiroki Shirato
Journal:  EJNMMI Res       Date:  2017-02-27       Impact factor: 3.138

Review 8.  Immunoglobulin G4-related hypertrophic pachymeningitis: A case-oriented review.

Authors:  Michaël Levraut; Mikaël Cohen; Saskia Bresch; Caroline Giordana; Fanny Burel-Vandenbos; Lydiane Mondot; Jacques Sedat; Denys Fontaine; Véronique Bourg; Nihal Martis; Christine Lebrun-Frenay
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-05-07

9.  First Report of IgG4 Related Disease Primary Presenting as Vertebral Bone Marrow Lesions.

Authors:  Debby van den Elshout-den Uyl; Clothaire P E Spoto; Mirthe de Boer; Tim Leiner; Helen L Leavis; Roos J Leguit
Journal:  Front Immunol       Date:  2019-08-13       Impact factor: 7.561

Review 10.  Therapeutic approach to IgG4-related disease: A systematic review.

Authors:  Pilar Brito-Zerón; Belchin Kostov; Xavier Bosch; Nihan Acar-Denizli; Manuel Ramos-Casals; John H Stone
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.